Raymond James Reinstates Outperform on Neurocrine Biosciences, Announces $155 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) with a price target of $155.
October 10, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Neurocrine Biosciences with a $155 price target, indicating a positive outlook for the stock.
The reinstatement of an Outperform rating by a reputable analyst and a specific price target of $155 suggests a positive short-term impact on NBIX's stock price. This indicates confidence in the company's performance and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100